IsoRay, Inc. (NYSEAMERICAN:ISR) shares shot up 7.7% during trading on Tuesday . The company traded as high as $0.44 and last traded at $0.42. 679,593 shares traded hands during mid-day trading, an increase of 284% from the average session volume of 176,778 shares. The stock had previously closed at $0.39.

A number of brokerages have commented on ISR. HC Wainwright set a $1.00 price objective on IsoRay and gave the company a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research downgraded IsoRay from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th.

IsoRay (NYSEAMERICAN:ISR) last released its earnings results on Tuesday, February 12th. The healthcare company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.76 million.

Large investors have recently added to or reduced their stakes in the company. Highland Private Wealth Management bought a new stake in shares of IsoRay during the 4th quarter valued at $39,000. Vanguard Group Inc. lifted its position in shares of IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after acquiring an additional 367,324 shares during the period. Finally, Vanguard Group Inc lifted its position in shares of IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after acquiring an additional 367,324 shares during the period.

TRADEMARK VIOLATION NOTICE: “IsoRay (ISR) Shares Up 7.7%” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/isoray-isr-shares-up-7-7/2983109.html.

IsoRay Company Profile (NYSEAMERICAN:ISR)

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Featured Story: Why is total return important?

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.